



SERES
THERAPEUTICS™

Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences

January 29, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 29, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will participate in two investor conferences in February:

- Canaccord Genuity Rare Disease, BioPharma One-on-One Day on Tuesday, Feb. 2, 2016 in New York, NY.
- Leerink Partners Global Healthcare Conference on Feb. 10 – 11, 2016 in New York, NY.

Roger Pomerantz, M.D., Chairman, President and CEO of Seres, will participate in a question and answer session on the first day of the Leerink Partners Global Healthcare Conference. The session will be available under the Investors and Media section of Seres' website at www.serestherapeutics.com. A replay of the session will become available approximately one hour after the event and will be archived on the site for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome characterized by an increased presence of pathogenic bacterial species, where the natural state of bacterial diversity is imbalanced. Seres' most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring *Clostridium difficile* infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC).



View source version on businesswire.com: <http://www.businesswire.com/news/home/20160129005817/en/>

Source: Seres Therapeutics, Inc.

IR Contact:

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com

or

PR Contact:

Ten Bridge Communications
Dan Quinn, 781-475-7974
Dan@tenbridgecommunications.com